Altimmune (ALT) Return on Sales (2010 - 2025)

Altimmune (ALT) has 16 years of Return on Sales data on file, last reported at 22.27% in Q4 2025.

• Return on Sales for Q4 2025 came in at 22.27%, up 6863.0% year-over-year; the trailing twelve-month figure through Dec 2025 was 0.69% (up 4684.0% YoY), and the FY2025 annual result was 0.69%, up 4684.0% from the prior year.
• Return on Sales improved to 22.27% in Q4 2025 per ALT's latest filing, from 38.03% in the prior quarter.
• Over five years, Return on Sales peaked at 22.27% in Q4 2025 and troughed at 117.58% in Q3 2022.
• A 5-year average of 23.11% and a median of 17.37% in 2022 frame the typical range for Return on Sales.
• The sharpest annual moves came in 2022 and 2023: Return on Sales slumped 11546 bps in 2022, then jumped 11701 bps in 2023.
• A 5-year view of Return on Sales shows it stood at 0.02% in 2021, then jumped by 119745 bps to 19.65% in 2022, then sank by 112 bps to 2.4% in 2023, then sank by 1829 bps to 46.36% in 2024, then surged by 148 bps to 22.27% in 2025.
• Business Quant data shows ALT's Return on Sales at 22.27% in Q4 2025, 38.03% in Q3 2025, and 44.29% in Q2 2025.